Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
Recursion Pharmaceuticals (RXRX) closed at $5.91 in the latest trading session, marking a -6.19% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.23% for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback